Alpha Emitter Market Forecast To Reach USD 1.57 Billion By 2031, Driven By Expanding Oncology Use And Targeted Radiotherapy Demand

(MENAFN- GetNews)

Mordor Intelligence has published a new report on the alpha emitter market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

According to Mordor Intelligence, the alpha emitter market size is valued at USD 0.92 billion in 2026, and is forecast to grow to USD 1.57 billion by 2031. This outlook reflects rising clinical confidence in alpha-particle therapies and growing investment across the alpha emitter industry.

Alpha emitters are being integrated into cancer care due to their ability to deliver high-energy radiation directly to tumor cells while limiting damage to surrounding tissue. This treatment approach is becoming relevant for cancers that do not respond well to surgery, chemotherapy, or beta-based radiotherapies. As a result, the alpha emitter market size continues to expand alongside demand for precise and localized cancer treatments.

Alpha Emitter Market Trends Shaping Industry Demand

Rising Clinical Focus on Hard-to-Treat Cancers

One of the most visible alpha emitter market trends is the growing use of alpha therapies for cancers that show resistance to conventional treatment. Prostate cancer and bone-related metastases remain key focus areas, but clinical pipelines are gradually expanding into ovarian, pancreatic, and endocrine tumors. This shift is supporting consistent alpha emitter market growth across multiple therapeutic segments.

Growing Confidence in High-Precision Radiotherapy

Clinicians are increasingly comfortable using alpha emitters due to their short radiation range and targeted impact. This precision allows treatment of micro-metastatic disease while reducing systemic side effects. As clinical evidence accumulates, alpha emitters are moving from late-stage or salvage therapy into earlier treatment settings, strengthening the overall alpha emitter market share outlook.

Pharmaceutical Investment and Strategic Partnerships

Another defining trend in the alpha emitter industry is sustained investment from established pharmaceutical companies. Strategic acquisitions, licensing agreements, and isotope supply partnerships are helping companies secure long-term access to critical radionuclides. These efforts are accelerating clinical development timelines and reinforcing competitive positioning within the alpha emitter market.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:

Alpha Emitter Market Segmentation Analysis

• By Type of Radionuclide

• Astatine-211

• Radium-223

• Actinium-225

• Lead-212

• Bismuth-212

• Other Radionuclides

• By Application

• Prostate Cancer

• Bone Metastasis

• Ovarian Cancer

• Pancreatic Cancer

• Endocrine Tumors

• Other Applications

• By End User

• Hospitals

• Diagnostic Centers

• Other End Users

• By Geography

• North America

• United States

• Canada

• Mexico

• Europe

• Germany

• United Kingdom

• France

• Italy

• Spain

• Rest of Europe

• Asia-Pacific

• China

• Japan

• India

• South Korea

• Australia

• Rest of Asia-Pacific

• Middle East and Africa

• GCC

• South Africa

• Rest of Middle East and Africa

• South America

• Brazil

• Argentina

• Rest of South Americ

Alpha Emitter Market Industry Players

The alpha emitter market features a competitive yet moderately concentrated landscape. Leading companies focus on securing isotope supply, advancing clinical pipelines, and strengthening global reach.

Key players active in the alpha emitter industry include:

• Bayer AG

• Novartis AG

• Actinium Pharmaceuticals

• Telix Pharmaceuticals

• Fusion Pharmaceuticals

Alpha Emitter Market Conclusion

The alpha emitter market forecast indicates sustained expansion as precision oncology becomes a priority in cancer care. Improvements in isotope production, combined with expanding clinical acceptance, are gradually addressing historical supply and infrastructure limitations.

While adoption still requires specialized facilities and trained personnel, ongoing collaboration between healthcare providers and pharmaceutical companies is helping reduce operational barriers. As treatment protocols mature and reimbursement pathways become clearer, the alpha emitter market growth trajectory is expected to remain steady.

Industry Related Reports:

Neuromodulation Market Size: The Neuromodulation Market is valued at USD 7.22 billion in 2026 and is projected to reach USD 10.93 billion by 2031, growing at a CAGR of 8.64% during the forecast period.

Optogenetics Market Share: The Optogenetics Market, segmented by product type, application, end user, and geography, is valued at USD 600.2 billion in 2025 and is expected to reach USD 740.48 billion by 2030, registering a CAGR of 4.29%.

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

...

MENAFN17022026003238003268ID1110753876